Wockhardt Intrinsic Value
Wockhardt (WOCKPHARMA) median intrinsic value is ₹900.24 from 9 valuation models (range ₹531–₹1442), vs current price ₹1771.00 — -49.2% downside (Trading Above Calculated Value), margin of safety -96.7%. For current market price and key ratios, visit Wockhardt screener.
WOCKPHARMA Valuation Methods Summary — DCF, Graham Number & P/E
Wockhardt intrinsic value across 9 models vs current price ₹1771.00 — upside/downside and value range per method. Also explore WOCKPHARMA share price history to track price trends across different timeframes.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹900.24 | ₹720.19 - ₹1080.29 | -49.2% | EPS: ₹40.92, Sector P/E: 22x |
| Book Value Method | asset | ₹1149.88 | ₹1034.89 - ₹1264.87 | -35.1% | Book Value/Share: ₹574.94, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1019.26 | ₹917.33 - ₹1121.19 | -42.4% | Revenue/Share: ₹509.63, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1441.98 | ₹1297.78 - ₹1586.18 | -18.6% | EBITDA: ₹1168.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹708.40 | ₹566.72 - ₹850.08 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹531.30 | ₹478.17 - ₹584.43 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹632.21 | ₹568.99 - ₹695.43 | -64.3% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹971.85 | ₹874.67 - ₹1069.04 | -45.1% | ROE: 14.1%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹727.56 | ₹654.80 - ₹800.32 | -58.9% | EPS: ₹40.92, BVPS: ₹574.94 |
WOCKPHARMA Intrinsic Value vs Market Price — All Valuation Models
Wockhardt fair value range ₹531–₹1442 vs current market price ₹1771.00 across 9 valuation models. Browse WOCKPHARMA financial statements for revenue, profit, balance sheet and cash flow data.
WOCKPHARMA Intrinsic Value Analysis — Undervalued or Overvalued?
Wockhardt median intrinsic value ₹900.24, current price ₹1771.00 — Trading Above Calculated Value by 49.2%, margin of safety -96.7%.
What is the intrinsic value of WOCKPHARMA?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Wockhardt (WOCKPHARMA) is ₹900.24 (median value). With the current market price of ₹1771.00, this represents a -49.2% variance from our estimated fair value.
The valuation range spans from ₹531.30 to ₹1441.98, indicating ₹531.30 - ₹1441.98.
Is WOCKPHARMA undervalued or overvalued?
Based on our multi-method analysis, Wockhardt (WOCKPHARMA) appears to be trading above calculated value by approximately 49.2%.
WOCKPHARMA Financial Health — Key Ratios vs Industry Benchmarks
Wockhardt financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.72 | Industry Standard: 2.0+ | Above 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 14.1% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 23.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.51x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
WOCKPHARMA Cash Flow Quality — Operating & Free Cash Flow
Wockhardt operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-22 Cr | ₹-412 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹219 Cr | ₹150 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹153 Cr | ₹94 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹413 Cr | ₹311 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹-287 Cr | ₹-287 Cr | Negative Cash Flow | 3/10 |